Table 4 Willingness to pay and willingness to trade efficacy for osteoporosis medication attributes a
From: Patients’ preferences for osteoporosis drug treatment: a discrete-choice experiment
Attributes and levels | Willingness to pay | Willingness to trade efficacy |
|---|---|---|
(€ per month) | (% risk reduction) | |
Efficacy (1% risk reduction) | 3.73 (3.01 to 4.44) | – |
Cost (€1) | – | -2.27 (–1.58 to –2.96) |
Drug administration (reference level: weekly oral tablet) | ||
Monthly oral tablet | 16.16 (12.85 to 19.47) | -10.16 (–7.88 to –12.50) |
Subcutaneous injection 3-monthly | 4.24 (3.72 to 4.76) | -2.93 (–2.57 to –3.30) |
Subcutaneous injection 6-monthly | 19.53 (17.15 to 21.92) | -13.52 (–11.82 to –15.22) |
Intravenous injection 3-monthly | -15.28 (–23.23 to –7.34) | 8.66 (14.31 to 3.01) |
Intravenous injection yearly | 11.75 (5.64 to 17.85) | -5.83 (–1.88 to –9.77) |
Side-effects (reference level: gastrointestinal disorders) | ||
Flu-like symptoms | 25.21 (13.06 to 20.50) | -16.68 (–14.20 to –19.16) |
Skin reactions | 16.78 (13.06 to 20.50) | -9.48 (–7.13 to –11.83) |